MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

An NBCUniversal press release about upcoming movies that will stream on Peacock unintentionally revealed that the sequel to ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking ... and good afternoon, everyone. Thank you for joining us for VIR ...

Good day, and thank you for standing by. Welcome to the Legend Biotech’s First Quarter 2025 ... During today's call, we will be making forward-looking statements, which are subject to risks ...

HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing ...

Welcome to Zymeworks first-quarter 2025 results conference call and webcast. (Operator Instructions) I would now like to turn the conference over to Shrinal Inamdar, Senior Director of Investor ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... excellent efficacy in third-line NSCLC to date and we look forward to presenting our findings at ASCO 2025 on May 31 st.” Poster ...